DXCMDexcom, Inc. KPI Monitor
Public package
Public baseline through 2026-07-30

Operating leverage with double-digit revenue growth and improving GAAP margins.

BUY under the locked decision engine; intrinsic value remains scenario-sensitive.

Posture
BUY under the locked decision engine; intrinsic value remains scenario-sensitive.
Business phase
4
Next proof
Growth gate, Margin gate, Cash and dilution gate
Valuation
Unavailable
Revenue
$1.3B
Q2 FY2026 · Dexcom Q2 2026 Form 10-Q (2026-07-30)
Gross profit
$830M
Q2 FY2026 · Dexcom Q2 2026 Form 10-Q (2026-07-30)
Operating income / EBIT
$318.3M
Q2 FY2026 · Dexcom Q2 2026 Form 10-Q (2026-07-30)
Gross margin
63.4%
Q2 FY2026 · Dexcom Q2 2026 Form 10-Q (2026-07-30)
Operating cash flow
$794.8M
2026-06-30 · Dexcom Q2 2026 Form 10-Q (2026-07-30)

Ranked KPI scorecard

#KPIBaselineNext thresholdSignalInvestor readSource
1 RevenueQ2 FY2026 $1.3B Stay at or above $1.2B Above floor The latest result remains on the safe side of the warning threshold. Dexcom Q2 2026 Form 10-Q (2026-07-30)
2 Gross profitQ2 FY2026 $830M Next comparable update Monitor No comparable prior observation is in the public handoff; judge the next update against this baseline. Dexcom Q2 2026 Form 10-Q (2026-07-30)
3 Operating income / EBITQ2 FY2026 $318.3M Next comparable update Monitor No comparable prior observation is in the public handoff; judge the next update against this baseline. Dexcom Q2 2026 Form 10-Q (2026-07-30)
4 Gross marginQ2 FY2026 63.4% Stay at or above 60% Near threshold The KPI is still on the safe side, but close enough that the next update matters. Dexcom Q2 2026 Form 10-Q (2026-07-30)
5 Operating cash flow2026-06-30 $794.8M Next comparable update Monitor No comparable prior observation is in the public handoff; judge the next update against this baseline. Dexcom Q2 2026 Form 10-Q (2026-07-30)
6 Operating marginQ2 FY2026 24.3% Stay at or above 17% Above floor The latest result remains on the safe side of the warning threshold. Dexcom Q2 2026 Form 10-Q (2026-07-30)
7 Net income attributable to commonQ2 FY2026 $249.1M Next comparable update Monitor No comparable prior observation is in the public handoff; judge the next update against this baseline. Dexcom Q2 2026 Form 10-Q (2026-07-30)
8 Diluted weighted-average sharesQ2 FY2026 390.1M Stay at or below 400M Near threshold The KPI is still on the safe side, but close enough that the next update matters. Dexcom Q2 2026 Form 10-Q (2026-07-30)
9 Capital expenditures2026-06-30 $161.3M Next comparable update Monitor No comparable prior observation is in the public handoff; judge the next update against this baseline. Dexcom Q2 2026 Form 10-Q (2026-07-30)
10 Interest ExpenseQ2 FY2026 $2.2M Next comparable update Monitor No comparable prior observation is in the public handoff; judge the next update against this baseline. Dexcom Q2 2026 Form 10-Q (2026-07-30)
11 Total debt2026-06-30 $1.2B Next comparable update Monitor No comparable prior observation is in the public handoff; judge the next update against this baseline. Dexcom Q2 2026 Form 10-Q (2026-07-30)
12 Free cash flow2026-06-30 $633.5M Stay at or above $0 Above floor The latest result remains on the safe side of the warning threshold. Dexcom Q2 2026 Form 10-Q (2026-07-30)
13 Cash and equivalents2026-06-30 $1.1B Next comparable update Monitor No comparable prior observation is in the public handoff; judge the next update against this baseline. Dexcom Q2 2026 Form 10-Q (2026-07-30)
14 Net IncomeQ2 FY2026 $249.1M Next comparable update Monitor No comparable prior observation is in the public handoff; judge the next update against this baseline. Dexcom Q2 2026 Form 10-Q (2026-07-30)

How to read the scorecard: Signals compare the latest baseline with the stated decision threshold. “Monitor” means the public handoff has one valid baseline but no compatible prior observation; it is not a positive or negative call.

KPI ontology coverage

Company definitions: 0. Coverage: No compatible sector, subsector, or business-model module was evidenced.; Company definition is supported only by private or local provenance.; Company definition is supported only by private or local provenance.; Company definition is supported only by private or local provenance.; Company definition is supported only by private or local provenance.; Company definition is supported only by private or local provenance.; Company definition is supported only by private or local provenance.; Company definition is supported only by private or local provenance.; Company definition is supported only by private or local provenance.; Company definition is supported only by private or local provenance.

ModuleLevelVersion
Special situationscross_cuttingv1
Universal financial coreuniversalv1

Quarterly KPI trajectory

Coverage: 117 reported observations across a 12-quarter snapshot; 41 explicit gaps. 44 derived from aligned ytd, 73 reported. Acquisition status: not public.

KPICurrentPrevious quarterYear agoQoQYoYEight-quarter trendManagement explanationInvestor interpretationSource
Interest Expense$2.2M (Q2 FY2026)$2.1M (Q1 FY2026)$3.8M (Q2 FY2025)+4.8%-42.1%$3.7M → $3.8M → $3.7M → $3.7M → $3.8M → $3.7M → $2.1M → $2.2MNo supported explanationimproving; no threshold configured; confidence highPrimary source (2026-07-30)
Net Income$249.1M (Q2 FY2026)$199.5M (Q1 FY2026)$179.8M (Q2 FY2025)+24.9%+38.5%$146.4M → $143.5M → $134.6M → $105.4M → $179.8M → $283.8M → $199.5M → $249.1MThe accepted Q2 filing reports the GAAP measures but does not provide a quantified driver bridge for every line; the related move is retained as an explicit unexplained reported change rather than attributed to a single cause. (unknown)improving; no threshold configured; confidence highPrimary source (2026-07-30)
Capital expenditures$84.7M (Q2 FY2026)$76.6M (Q1 FY2026)$94.1M (Q2 FY2025)+10.6%-10.0%$56.9M → $66.1M → $111.2M → $87M → $94.1M → $80.5M → $76.6M → $84.7MThe accepted Q2 filing reports the GAAP measures but does not provide a quantified driver bridge for every line; the related move is retained as an explicit unexplained reported change rather than attributed to a single cause. (unknown)improving; no threshold configured; confidence highPrimary source (2026-07-30)
Cash and equivalents$1.1B (Q2 FY2026)$1.1BNo supported explanationinsufficient_data; no threshold configured; confidence lowPrimary source (2026-07-30)
Diluted EPS0.64 (Q2 FY2026)0.51 (Q1 FY2026)0.45 (Q2 FY2025)+25.5%+42.2%0.36 → 0.35 → 0.34 → 0.27 → 0.45 → 0.7 → 0.51 → 0.64The accepted Q2 filing reports the GAAP measures but does not provide a quantified driver bridge for every line; the related move is retained as an explicit unexplained reported change rather than attributed to a single cause. (unknown)improving; no threshold configured; confidence highPrimary source (2026-07-30)
Diluted weighted-average shares390.1M (Q2 FY2026)393.6M (Q1 FY2026)408.2M (Q2 FY2025)-0.9%-4.4%416.7M → 416.8M → 410.2M → 407.5M → 408.2M → 407.4M → 393.6M → 390.1MNo supported explanationimproving; no threshold configured; confidence highPrimary source (2026-07-30)
Free cash flow$184.5M (Q2 FY2026)$449M (Q1 FY2026)$208.9M (Q2 FY2025)-58.9%-11.7%$152.3M → $213.3M → $88.3M → $96.8M → $208.9M → $579.4M → $449M → $184.5MThe accepted Q2 filing reports the GAAP measures but does not provide a quantified driver bridge for every line; the related move is retained as an explicit unexplained reported change rather than attributed to a single cause. (unknown)deteriorating; no threshold configured; confidence highPrimary source (2026-07-30)
Gross margin63.4% (Q2 FY2026)62.9% (Q1 FY2026)59.5% (Q2 FY2025)+49 bps+391 bps61% → 62.4% → 59.7% → 56.9% → 59.5% → 60.5% → 62.9% → 63.4%No supported explanationimproving; no threshold configured; confidence highPrimary source (2026-07-30)
Gross profit$830M (Q2 FY2026)$750.3M (Q1 FY2026)$688.8M (Q2 FY2025)+10.6%+20.5%$561.9M → $626.7M → $593.8M → $589M → $688.8M → $731.4M → $750.3M → $830MThe accepted Q2 filing reports the GAAP measures but does not provide a quantified driver bridge for every line; the related move is retained as an explicit unexplained reported change rather than attributed to a single cause. (unknown)improving; no threshold configured; confidence highPrimary source (2026-07-30)
Net income attributable to common$249.1M (Q2 FY2026)$199.5M (Q1 FY2026)$179.8M (Q2 FY2025)+24.9%+38.5%$146.4M → $143.5M → $134.6M → $105.4M → $179.8M → $283.8M → $199.5M → $249.1MThe accepted Q2 filing reports the GAAP measures but does not provide a quantified driver bridge for every line; the related move is retained as an explicit unexplained reported change rather than attributed to a single cause. (unknown)improving; no threshold configured; confidence highPrimary source (2026-07-30)
Operating cash flow$269.2M (Q2 FY2026)$525.6M (Q1 FY2026)$303M (Q2 FY2025)-48.8%-11.2%$209.2M → $279.4M → $199.5M → $183.8M → $303M → $659.9M → $525.6M → $269.2MThe accepted Q2 filing reports the GAAP measures but does not provide a quantified driver bridge for every line; the related move is retained as an explicit unexplained reported change rather than attributed to a single cause. (unknown)deteriorating; no threshold configured; confidence highPrimary source (2026-07-30)
Operating income / EBIT$318.3M (Q2 FY2026)$255.3M (Q1 FY2026)$212.6M (Q2 FY2025)+24.7%+49.7%$101.1M → $158M → $152M → $133.7M → $212.6M → $242.5M → $255.3M → $318.3MThe accepted Q2 filing reports the GAAP measures but does not provide a quantified driver bridge for every line; the related move is retained as an explicit unexplained reported change rather than attributed to a single cause. (unknown)improving; no threshold configured; confidence highPrimary source (2026-07-30)
Operating margin24.3% (Q2 FY2026)21.4% (Q1 FY2026)18.4% (Q2 FY2025)+291 bps+595 bps11% → 15.7% → 15.3% → 12.9% → 18.4% → 20.1% → 21.4% → 24.3%No supported explanationimproving; no threshold configured; confidence highPrimary source (2026-07-30)
Revenue$1.3B (Q2 FY2026)$1.2B (Q1 FY2026)$1.2B (Q2 FY2025)+9.8%+13.1%$921M → $1B → $994.2M → $1B → $1.2B → $1.2B → $1.2B → $1.3BNo supported explanationimproving; no threshold configured; confidence highPrimary source (2026-07-30)
Complete 12-quarter reported history
KPIPeriodValueQoQYoYSource
Capital expendituresQ2 FY2026$84.7M+10.6%-10.0%Primary source (2026-07-30)
Capital expendituresQ1 FY2026$76.6M-12.0%Primary source (2026-04-30)
Capital expendituresQ3 FY2025$80.5M-14.5%-27.6%Primary source (2025-10-30)
Capital expendituresQ2 FY2025$94.1M+8.2%+42.4%Primary source (2025-07-30)
Capital expendituresQ1 FY2025$87M+52.9%Primary source (2025-05-01)
Capital expendituresQ3 FY2024$111.2M+68.2%-39.6%Primary source (2024-10-24)
Capital expendituresQ2 FY2024$66.1M+16.2%Primary source (2024-07-25)
Capital expendituresQ1 FY2024$56.9MPrimary source (2024-04-25)
Capital expendituresQ3 FY2023$184.1MPrimary source (2023-10-26)
Cash and equivalentsQ2 FY2026$1.1BPrimary source (2026-07-30)
Diluted EPSQ2 FY20260.64+25.5%+42.2%Primary source (2026-07-30)
Diluted EPSQ1 FY20260.51+88.9%Primary source (2026-04-30)
Diluted EPSQ3 FY20250.7+55.6%+105.9%Primary source (2025-10-30)
Diluted EPSQ2 FY20250.45+66.7%+28.6%Primary source (2026-07-30)
Diluted EPSQ1 FY20250.27-25.0%Primary source (2026-04-30)
Diluted EPSQ3 FY20240.34-2.9%+17.2%Primary source (2025-10-30)
Diluted EPSQ2 FY20240.35-2.8%Primary source (2025-07-30)
Diluted EPSQ1 FY20240.36Primary source (2025-05-01)
Diluted EPSQ3 FY20230.29Primary source (2024-10-24)
Diluted weighted-average sharesQ2 FY2026390.1M-0.9%-4.4%Primary source (2026-07-30)
Diluted weighted-average sharesQ1 FY2026393.6M-3.4%Primary source (2026-04-30)
Diluted weighted-average sharesQ3 FY2025407.4M-0.2%-0.7%Primary source (2025-10-30)
Diluted weighted-average sharesQ2 FY2025408.2M+0.2%-2.1%Primary source (2026-07-30)
Diluted weighted-average sharesQ1 FY2025407.5M-2.2%Primary source (2026-04-30)
Diluted weighted-average sharesQ3 FY2024410.2M-1.6%-3.9%Primary source (2025-10-30)
Diluted weighted-average sharesQ2 FY2024416.8M+0.0%Primary source (2025-07-30)
Diluted weighted-average sharesQ1 FY2024416.7MPrimary source (2025-05-01)
Diluted weighted-average sharesQ3 FY2023426.8MPrimary source (2024-10-24)
Free cash flowQ2 FY2026$184.5M-58.9%-11.7%Primary source (2026-07-30)
Free cash flowQ1 FY2026$449M+363.8%Primary source (2026-07-30)
Free cash flowQ3 FY2025$579.4M+177.4%+556.2%Primary source (2026-07-30)
Free cash flowQ2 FY2025$208.9M+115.8%-2.1%Primary source (2026-07-30)
Free cash flowQ1 FY2025$96.8M-36.4%Primary source (2026-07-30)
Free cash flowQ3 FY2024$88.3M-58.6%-79.5%Primary source (2026-07-30)
Free cash flowQ2 FY2024$213.3M+40.1%Primary source (2026-07-30)
Free cash flowQ1 FY2024$152.3MPrimary source (2026-07-30)
Free cash flowQ3 FY2023$430.8MPrimary source (2026-07-30)
Gross marginQ2 FY202663.4%+49 bps+391 bpsPrimary source (2026-07-30)
Gross marginQ1 FY202662.9%+610 bpsPrimary source (2026-04-30)
Gross marginQ3 FY202560.5%+95 bps+75 bpsPrimary source (2025-10-30)
Gross marginQ2 FY202559.5%+267 bps-287 bpsPrimary source (2026-07-30)
Gross marginQ1 FY202556.9%-416 bpsPrimary source (2026-04-30)
Gross marginQ3 FY202459.7%-268 bps-420 bpsPrimary source (2025-10-30)
Gross marginQ2 FY202462.4%+139 bpsPrimary source (2025-07-30)
Gross marginQ1 FY202461%Primary source (2025-05-01)
Gross marginQ3 FY202363.9%Primary source (2024-10-24)
Gross profitQ2 FY2026$830M+10.6%+20.5%Primary source (2026-07-30)
Gross profitQ1 FY2026$750.3M+27.4%Primary source (2026-04-30)
Gross profitQ3 FY2025$731.4M+6.2%+23.2%Primary source (2025-10-30)
Gross profitQ2 FY2025$688.8M+16.9%+9.9%Primary source (2026-07-30)
Gross profitQ1 FY2025$589M+4.8%Primary source (2026-04-30)
Gross profitQ3 FY2024$593.8M-5.2%-4.7%Primary source (2025-10-30)
Gross profitQ2 FY2024$626.7M+11.5%Primary source (2025-07-30)
Gross profitQ1 FY2024$561.9MPrimary source (2025-05-01)
Gross profitQ3 FY2023$623.3MPrimary source (2024-10-24)
Interest ExpenseQ2 FY2026$2.2M+4.8%-42.1%Primary source (2026-07-30)
Interest ExpenseQ1 FY2026$2.1M-43.2%Primary source (2026-04-30)
Interest ExpenseQ3 FY2025$3.7M-2.6%+0.0%Primary source (2025-10-30)
Interest ExpenseQ2 FY2025$3.8M+2.7%+0.0%Primary source (2026-07-30)
Interest ExpenseQ1 FY2025$3.7M+0.0%Primary source (2026-04-30)
Interest ExpenseQ3 FY2024$3.7M-2.6%Primary source (2025-10-30)
Interest ExpenseQ2 FY2024$3.8M+2.7%Primary source (2025-07-30)
Interest ExpenseQ1 FY2024$3.7MPrimary source (2025-05-01)
Net IncomeQ2 FY2026$249.1M+24.9%+38.5%Primary source (2026-07-30)
Net IncomeQ1 FY2026$199.5M+89.3%Primary source (2026-04-30)
Net IncomeQ3 FY2025$283.8M+57.8%+110.8%Primary source (2025-10-30)
Net IncomeQ2 FY2025$179.8M+70.6%+25.3%Primary source (2026-07-30)
Net IncomeQ1 FY2025$105.4M-28.0%Primary source (2026-04-30)
Net IncomeQ3 FY2024$134.6M-6.2%+11.5%Primary source (2025-10-30)
Net IncomeQ2 FY2024$143.5M-2.0%Primary source (2025-07-30)
Net IncomeQ1 FY2024$146.4MPrimary source (2025-05-01)
Net IncomeQ3 FY2023$120.7MPrimary source (2024-10-24)
Net income attributable to commonQ2 FY2026$249.1M+24.9%+38.5%Primary source (2026-07-30)
Net income attributable to commonQ1 FY2026$199.5M+89.3%Primary source (2026-04-30)
Net income attributable to commonQ3 FY2025$283.8M+57.8%+110.8%Primary source (2025-10-30)
Net income attributable to commonQ2 FY2025$179.8M+70.6%+25.3%Primary source (2026-07-30)
Net income attributable to commonQ1 FY2025$105.4M-28.0%Primary source (2026-04-30)
Net income attributable to commonQ3 FY2024$134.6M-6.2%+11.5%Primary source (2025-10-30)
Net income attributable to commonQ2 FY2024$143.5M-2.0%Primary source (2025-07-30)
Net income attributable to commonQ1 FY2024$146.4MPrimary source (2025-05-01)
Net income attributable to commonQ3 FY2023$120.7MPrimary source (2024-10-24)
Operating cash flowQ2 FY2026$269.2M-48.8%-11.2%Primary source (2026-07-30)
Operating cash flowQ1 FY2026$525.6M+186.0%Primary source (2026-04-30)
Operating cash flowQ3 FY2025$659.9M+117.8%+230.8%Primary source (2025-10-30)
Operating cash flowQ2 FY2025$303M+64.9%+8.4%Primary source (2025-07-30)
Operating cash flowQ1 FY2025$183.8M-12.1%Primary source (2025-05-01)
Operating cash flowQ3 FY2024$199.5M-28.6%-67.6%Primary source (2024-10-24)
Operating cash flowQ2 FY2024$279.4M+33.6%Primary source (2024-07-25)
Operating cash flowQ1 FY2024$209.2MPrimary source (2024-04-25)
Operating cash flowQ3 FY2023$614.9MPrimary source (2023-10-26)
Operating income / EBITQ2 FY2026$318.3M+24.7%+49.7%Primary source (2026-07-30)
Operating income / EBITQ1 FY2026$255.3M+90.9%Primary source (2026-04-30)
Operating income / EBITQ3 FY2025$242.5M+14.1%+59.5%Primary source (2025-10-30)
Operating income / EBITQ2 FY2025$212.6M+59.0%+34.6%Primary source (2026-07-30)
Operating income / EBITQ1 FY2025$133.7M+32.2%Primary source (2026-04-30)
Operating income / EBITQ3 FY2024$152M-3.8%-26.0%Primary source (2025-10-30)
Operating income / EBITQ2 FY2024$158M+56.3%Primary source (2025-07-30)
Operating income / EBITQ1 FY2024$101.1MPrimary source (2025-05-01)
Operating income / EBITQ3 FY2023$205.5MPrimary source (2024-10-24)
Operating marginQ2 FY202624.3%+291 bps+595 bpsPrimary source (2026-07-30)
Operating marginQ1 FY202621.4%+851 bpsPrimary source (2026-04-30)
Operating marginQ3 FY202520.1%+168 bps+476 bpsPrimary source (2025-10-30)
Operating marginQ2 FY202518.4%+547 bps+264 bpsPrimary source (2026-07-30)
Operating marginQ1 FY202512.9%+193 bpsPrimary source (2026-04-30)
Operating marginQ3 FY202415.3%-44 bps-579 bpsPrimary source (2025-10-30)
Operating marginQ2 FY202415.7%+476 bpsPrimary source (2025-07-30)
Operating marginQ1 FY202411%Primary source (2025-05-01)
Operating marginQ3 FY202321.1%Primary source (2024-10-24)
RevenueQ2 FY2026$1.3B+9.8%+13.1%Primary source (2026-07-30)
RevenueQ1 FY2026$1.2B+15.0%Primary source (2026-04-30)
RevenueQ3 FY2025$1.2B+4.5%+21.6%Primary source (2025-10-30)
RevenueQ2 FY2025$1.2B+11.7%+15.2%Primary source (2026-07-30)
RevenueQ1 FY2025$1B+12.5%Primary source (2026-04-30)
RevenueQ3 FY2024$994.2M-1.0%+2.0%Primary source (2025-10-30)
RevenueQ2 FY2024$1B+9.0%Primary source (2025-07-30)
RevenueQ1 FY2024$921MPrimary source (2025-05-01)
RevenueQ3 FY2023$975MPrimary source (2024-10-24)

Thesis signals

Thesis pillars

  • Adoption sustains double-digit growthBroader access, patient starts, and recurring sensor use keep quarterly revenue above the operating baseline.
  • Manufacturing and mix produce operating leverageGross-margin recovery converts revenue growth into faster operating-income growth.
  • Cash generation funds innovationPositive free cash flow and modest net debt support product cadence without external financing.
  • Per-share economics remain intactDiluted shares remain controlled while earnings and intrinsic cash flow grow.

Catalysts

  • Access expansionCoverage expansion and penetration beyond intensive insulin users can enlarge the addressable base.
  • Product cadenceG7 15-Day, Stelo and G8 milestones can improve reach, experience and retention.

Risks

  • Quality and reliabilityA material product-quality event could damage trust, adoption and remediation costs.
  • Competition, reimbursement and regulationPricing, access, approval or product pressure could slow starts and compress margins.

Monitoring triggers

  • Growth gateactive
  • Margin gateactive
  • Cash and dilution gateactive

Evidence limits

Conflicts

  • None reported.

Gaps

  • Itemgap

Public sources

  1. Primary source (2026-07-30)
  2. Primary source (2026-04-30)